Plain-English translation of NCT06234137 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a combination of four medications—, , , and —given before surgery to treat locally advanced HER2-positive breast cancer. The goal is to see if this treatment can shrink tumors enough that surgery removes all cancer cells. Researchers will follow participants for years afterward to track how well the treatment works and any side effects.
HER2-positive breast cancer is an aggressive type that needs strong treatment. Doctors want to know if this new four-drug combination, given before surgery, can help more patients achieve complete remission and live longer without their cancer returning.
You likely qualify if…
You likely don't qualify if…
You would take the four medications by mouth and/or intravenous infusion over six cycles (rounds) of treatment, with visits to the clinic for each cycle. During this time, doctors will monitor you closely with blood tests, heart imaging, and scans to track how well the treatment is working. After completing the six cycles, you would have surgery to remove the breast tumor. Following surgery, you would return for follow-up appointments and scans for several years to watch for cancer recurrence and monitor your long-term health.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China